Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXS NASDAQ:DOMH NASDAQ:VNDA NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXSCodexis$2.88+0.7%$2.50$1.90▼$6.08$236.94M2.52754,857 shs627,484 shsDOMHDominari$5.61+2.0%$5.25$0.83▼$13.58$80.54M0.61208,673 shs316,874 shsVNDAVanda Pharmaceuticals$4.86+1.0%$4.52$3.81▼$6.37$283.48M0.68596,164 shs326,615 shsVSTMVerastem$5.11-2.7%$5.97$2.10▼$9.10$288.48M0.711.30 million shs1.26 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXSCodexis+1.78%-1.72%+27.68%+35.55%-22.91%DOMHDominari+5.36%+10.66%+9.56%+37.84%+195.70%VNDAVanda Pharmaceuticals+1.05%-4.18%+5.02%+11.09%-22.79%VSTMVerastem+7.36%+9.15%-6.91%-8.54%+42.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXSCodexis3.4839 of 5 stars3.31.00.02.52.71.70.6DOMHDominari0.7993 of 5 stars0.02.00.00.02.22.50.6VNDAVanda Pharmaceuticals4.7021 of 5 stars3.84.00.04.21.53.31.3VSTMVerastem3.1245 of 5 stars3.55.00.00.01.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXSCodexis 2.50Moderate Buy$11.00281.94% UpsideDOMHDominari 0.00N/AN/AN/AVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50239.51% UpsideVSTMVerastem 3.00Buy$13.38161.74% UpsideCurrent Analyst Ratings BreakdownLatest DOMH, VNDA, VSTM, and CDXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.005/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.005/13/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/7/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXSCodexis$59.35M4.02N/AN/A$0.82 per share3.51DOMHDominari$18.15M4.53N/AN/A$5.71 per share0.98VNDAVanda Pharmaceuticals$198.77M1.44N/AN/A$9.24 per share0.53VSTMVerastem$10K28,079.45N/AN/A($0.65) per share-7.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXSCodexis-$65.28M-$0.99N/AN/AN/A-149.47%-118.47%-53.37%8/6/2025 (Estimated)DOMHDominari-$14.70M-$4.50N/A∞N/A-167.73%-91.67%-77.80%8/6/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)Latest DOMH, VNDA, VSTM, and CDXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDXSCodexis-$0.17N/AN/AN/AN/AN/A8/14/2025Q1 2025VSTMVerastem-$0.64N/AN/AN/A$6.01 millionN/A7/30/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34N/AN/AN/A$54.77 millionN/A5/14/2025Q1 2025CDXSCodexis-$0.20-$0.25-$0.05-$0.25$10.38 million$7.54 million5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/7/2025Q1 2025VNDAVanda Pharmaceuticals-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXSCodexisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXSCodexis0.593.723.64DOMHDominariN/A5.745.74VNDAVanda PharmaceuticalsN/A3.933.91VSTMVerastemN/A3.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXSCodexis78.54%DOMHDominari42.48%VNDAVanda Pharmaceuticals88.14%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipCDXSCodexis2.10%DOMHDominari32.98%VNDAVanda Pharmaceuticals10.00%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXSCodexis25082.85 million81.11 millionOptionableDOMHDominari414.64 million9.81 millionNot OptionableVNDAVanda Pharmaceuticals29058.93 million53.04 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableDOMH, VNDA, VSTM, and CDXS HeadlinesRecent News About These CompaniesVerastem: The Market Is Ignoring The ProgressJuly 16 at 8:42 AM | seekingalpha.comVerastem stock rises after LGSOC treatment data published in medical ...July 13, 2025 | investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...July 11, 2025 | gurufocus.comVerastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock NewsJuly 11, 2025 | gurufocus.comVerastem stock rises after LGSOC treatment data published in medical journalJuly 11, 2025 | in.investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical OncologyJuly 11, 2025 | businesswire.comVerastem, Inc. (VSTM) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comVerastem KRAS-Mutant Ovarian Cancer Treatment Activity Affirmed in Investigator-Initiated StudyJuly 8, 2025 | precisionmedicineonline.comPVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 8, 2025 | businesswire.comBTIG Remains a Buy on Verastem (VSTM)July 4, 2025 | theglobeandmail.comVerastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer TreatmentJuly 4, 2025 | tipranks.comVerastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian CancerJune 30, 2025 | businesswire.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from BrokeragesJune 28, 2025 | marketbeat.comVerastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related CancersJune 26, 2025 | seekingalpha.comFY2025 EPS Estimates for Verastem Cut by Cantor FitzgeraldJune 26, 2025 | marketbeat.comVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - MorningstarJune 26, 2025 | morningstar.comMRoyal Bank Of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock PriceJune 25, 2025 | marketbeat.comInsider Sell Alert: Daniel Calkins Sells Shares of Verastem Inc (VSTM)June 24, 2025 | gurufocus.comVerastem, Inc. (NASDAQ:VSTM) CFO Daniel Calkins Sells 4,110 SharesJune 24, 2025 | marketbeat.comDan Paterson Sells 17,808 Shares of Verastem, Inc. (NASDAQ:VSTM) StockJune 24, 2025 | marketbeat.comVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid TumorsJune 24, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDOMH, VNDA, VSTM, and CDXS Company DescriptionsCodexis NASDAQ:CDXS$2.88 +0.02 (+0.70%) Closing price 04:00 PM EasternExtended Trading$2.83 -0.05 (-1.74%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Dominari NASDAQ:DOMH$5.61 +0.11 (+2.00%) As of 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Vanda Pharmaceuticals NASDAQ:VNDA$4.86 +0.05 (+1.04%) Closing price 04:00 PM EasternExtended Trading$4.76 -0.11 (-2.16%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.Verastem NASDAQ:VSTM$5.11 -0.14 (-2.67%) Closing price 04:00 PM EasternExtended Trading$5.15 +0.04 (+0.78%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
